A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs BLZ 945 (Primary) ; PDR 001 (Primary)
- Indications Breast cancer; Glioblastoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 27 Oct 2016 Planned End Date changed from 1 Jun 2019 to 1 Oct 2019.
- 27 Oct 2016 Status changed from not yet recruiting to recruiting.
- 02 Oct 2016 Planned primary completion date changed from 1 Jun 2019 to 1 Oct 2019.